Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-
2. Leclaza
3. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide
1. 1903008-80-9
2. Yh-25448
3. Gns-1480
4. Yh25448
5. Gns1480
6. Jnj-73841937-aaa
7. Lazertinib [usan]
8. C-18112003-g
9. N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide
10. 4a2y23xk11
11. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide
12. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-
13. Leclaza
14. Lazertinib [inn]
15. Lazertinib [inn]
16. Lazertinib (yh25448)
17. Lazertinib [who-dd]
18. Unii-4a2y23xk11
19. Chembl4558324
20. Schembl17670400
21. Gtpl10136
22. Bcp30440
23. Ex-a1912
24. Bdbm50555575
25. S8724
26. Who 10587
27. Akos037515597
28. Ccg-270023
29. Lazertinib (yh25448,gns-1480)
30. Yh-25448;gns-1480
31. Ac-36243
32. Bs-15742
33. Compound 73 [wo2016060443a2]
34. Hy-109061
35. Cs-0032992
36. A16827
37. A903188
38. Yh-25448; Yh 25448; Yh25448; Gns-1480; Gns 1480; Gns1480
39. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide
40. N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
Molecular Weight | 554.6 g/mol |
---|---|
Molecular Formula | C30H34N8O3 |
XLogP3 | 3.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 10 |
Exact Mass | 554.27538698 g/mol |
Monoisotopic Mass | 554.27538698 g/mol |
Topological Polar Surface Area | 110 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 837 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Registrant Name : Yuhan Chemical Co., Ltd.
Registration Date : 2021-01-18
Registration Number : 1791-9-ND
Manufacturer Name : Yuhan Chemical Co., Ltd.
Manufacturer Address : 402, 5-ba, Sihwa Industrial Complex, 45 Jiwon-ro, Danwon-gu, Ansan-si, Gyeonggi-do (S...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) and dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer.
Lead Product(s): Amivantamab,Lazertinib,Dexamethasone
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2024
Lead Product(s) : Amivantamab,Lazertinib,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dexamethasone Reduces Infusion Reactions in EGFR-Mutated NSCLC Patients On RYBREVANT®
Details : Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) and dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 10, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Lead Product(s): Amivantamab,Lazertinib,Dexamethasone
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2024
Lead Product(s) : Amivantamab,Lazertinib,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
J&J's Chemotherapy-Free Treatment for Lung Cancer Gets US Approval
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 20, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Lead Product(s): Amivantamab,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2024
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amivantamab BLA Submitted to FDA for EGFR-Mutated Non-Small Cell Lung Cancer
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 17, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of exon 19 deletions or L858R mutated NSCLC.
Lead Product(s): Amivantamab,Lazertinib,Carboplatin
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2024
Lead Product(s) : Amivantamab,Lazertinib,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PALOMA-2 Shows Positive Results for Subcutaneous RYBREVANT® in EGFR-Mutated NSCLC
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of exon 19 deletions or L858R mutated NSCLC.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 03, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Lead Product(s): Amivantamab,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2024
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Phase 3 PALOMA-3 Shows Five-Fold Reduction in Reactions with Amivantamab Injection
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 31, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of EGFR-mutated NSCLC after failure of prior therapy.
Lead Product(s): Amivantamab,Lazertinib,Carboplatin
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2024
Lead Product(s) : Amivantamab,Lazertinib,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RYBREVANT® Plus Lazertinib Shows Longer PFS vs. Osimertinib in High-Risk NSCLC
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of EGFR-mutated NSCLC after failure of prior therapy.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 31, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody evaluated with lazertinib for first-line treatment of patients with EGFR-mutated non-small cell lung cancer.
Lead Product(s): Amivantamab,Lazertinib
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Janssen Submits Type II Extension for RYBREVANT and Lazertinib
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody evaluated with lazertinib for first-line treatment of patients with EGFR-mutated non-small cell lung cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 08, 2024
Details:
JNJ-73841937 (lazertinib) is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation. It is under phase 3 clinical development in combination with Rybrevant (amivantamab) for the treatment of EGFR-mutated non-small cell lung cancer.
Lead Product(s): Lazertinib,Amivantamab-vmjw
Therapeutic Area: Oncology Brand Name: JNJ-73841937
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Lead Product(s) : Lazertinib,Amivantamab-vmjw
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JNJ-73841937 (lazertinib) is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation. It is under phase 3 clinical development in combination with Rybrevant (amivantamab) for the treatment of EGFR-mutated non-small cell l...
Brand Name : JNJ-73841937
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2023
Details:
Rybrevant (amivantamab) is a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity. It is being evaluated in combination with lazertinib for the treatment of patients with EGFR-mutated non-small cell lung cancer.
Lead Product(s): Amivantamab,Lazertinib,Carboplatin
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Lead Product(s) : Amivantamab,Lazertinib,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rybrevant (amivantamab) is a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity. It is being evaluated in combination with lazertinib for the treatment of patients with EGFR-mutated non-small cell lung cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 21, 2023
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib & chemotherapy for the treatment of adult patients with advanced egfr-mutated non-small cell lung cancer after failure of prior therapy.
Lead Product(s): Amivantamab,Lazertinib,Pemetrexed
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Lead Product(s) : Amivantamab,Lazertinib,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Phase 3 MARIPOSA-2 Study Shows RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Given with or with...
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib & chemotherapy for the treatment of adult patients with advanced egfr-mutated non-small cell lung cancer after failure of prior th...
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 23, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?